Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript

Page 3 of 3

Anil Kapur: So that’s a clinical study, Joel. We do not provide updates on the enrollment, et cetera, projections within that space. The study is ongoing.

Joel Beatty: Okay, got it. Thanks. And then for the guidance of the cash runway into Q3 2025, what sales assumptions are going to that guidance?

Michelle Robertson: Sorry, Joel. I was on mute. We haven’t shared any sales guidance or revenue guidance just yet.

Joel Beatty: Got it, thank you.

Operator: And we have reached the end of our question-and-answer period. I will now turn the call back over to Aron Feingold for some final closing remarks.

Aron Feingold: Thank you everyone so much for joining us today. We appreciate your interest in Geron and look forward to keeping you updated. Be well.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect.

Follow Geron Corp (NASDAQ:GERN)

Page 3 of 3